NLS biotech-1

Norwegian biotech company Arxx Therapeutics will merge with Dutch pharma company Oxitope Pharma to create Calluna Pharma Inc. The merger followed a completed Series A round of EUR 75 million, led by the European investor Forbion, and included existing Arxx investors Sarsia, p53 and Investinor. The funding will last until late 2026, and will support […]

The Board of Directors of Xbrane Biopharma has announced a rights issue of units of approximately SEK 343 million, consisting of shares and warrants of series TO1. Upon full exercise of the warrants of series TO1, Xbrane will receive approximately up to an additional SEK 78 million. The Rights Issue is conditional upon approval by […]

The board of directors of Medivir has resolved on a directed issue through which the company receives approximately SEK 20 million before issue costs. The right to subscribe for shares in the Directed Issue shall, with deviation from the shareholders pre-emption rights, belong to Hallberg Management AB (HMAB). HMAB is controlled by Anders Hallberg, former […]

FluoGuide plans to expand the scope of application of FG001 and advance its development toward approval in aggressive brain cancer. FluoGuide has obtained clinical proof of concept of FG001, a fluorescent molecule targeting the cancer specific uPAR receptor, which lights up cancer cells to improve outcomes of surgery. This includes positive phase II data across […]

The manufacturing license paves the way for Anocca’s near-term path to the clinic and long-term strategy to advance franchises of precision targeted cell therapies for different cancers and covering diverse patient populations. Anocca has built validated asset franchises against valuable cancer targets including KRAS, PRAME and MAGE, with more than 40 preclinical assets in the […]

Nykode Therapeutics has announced an expansion of the pipeline with a potential first-in-class preclinical oncology vaccine program aimed at preventing and treating colorectal cancer. “The potential first-in-class program reaffirms Nykode’s vision of building a balanced cancer vaccine portfolio. We are excited about the transformative power of our next-generation technology with the potential to reduce the […]